Hepion Pharmaceuticals Inc. diskutieren
Hepion Pharmaceuticals Inc.
WKN: A3EEV3 / Symbol: HEPA / Name: Hepion Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
9,20 €
-
(Zielkurs erreicht)
Biotechnologie und medizinische Forschung
ContraVir Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen , Entwicklung Placement qui est konzentriert sich hauptsächlich auf die Entwicklung von Medikamenten Herpes - Zoster - Goldunternehmen zu behandeln shingles.The Zeit eine Verbindung Entwicklung genannt Expired FV-100 zur Behandlung von shingles.It est aussi CMX157 Entwicklung
ContraVir
Management hat den Kurs reingeritten - Boden scheint mir gefunden - Zeit die Fahrt wieder aufzunehmen
(Laufzeit überschritten)
(Laufzeit überschritten)
CTRV Pharma
Gutes Risk-/Reward-Verhältnis zu diesen Kursen! BUY!
SecteurRecherche biotechnologique et médicale
Operates as a development stage company
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline.
The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus.
ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline.
The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus.
ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.
Nombre d'employés : 21 personnes.
(Laufzeit überschritten)
(Vom Mitglied beendet)
Buy mit Kursziel 5,0
Buy Hepion Pharmaceuticals Inc.
Sell Hepion Pharmaceuticals Inc.
Buy Hepion Pharmaceuticals Inc.
Buy Hepion Pharmaceuticals Inc.
Buy Hepion Pharmaceuticals Inc.
Buy Hepion Pharmaceuticals Inc.
Sell Hepion Pharmaceuticals Inc.
Buy Hepion Pharmaceuticals Inc.
Buy Hepion Pharmaceuticals Inc.
Neueste Beiträge
RudolfL in Comfort Systems USA diskutieren